Biotechnology

Kangsters Unveils Revolutionary Treadmills at Rollettes Experience 2024: Celebrating Innovation and Empowerment

LOS ANGELES, July 10, 2024 /PRNewswire/ -- Kangsters, the pioneering South Korean adaptive tech startup, proudly announces its participation in the Rollettes Experience 2024. This renowned event, now celebrating its 11th anniversary, will be held fromJuly 11-14 at the Sheraton Hotel in Los Angele...

2024-07-11 00:00 2144

WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year

SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year t...

2024-07-10 13:30 3390

KOSÉ, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells

Demonstration testing of "my own" beauty products PALO ALTO, Calif., July 9, 2024 /PRNewswire/ -- KOSÉ Corporation (Headquarters: Chuo-ku,Tokyo; President: Kazutoshi Kobayashi), I Peace, Inc. (Headquarters:Palo Alto, California, USA; Founder & CEO: Koji Tanabe), and Reju, Inc. (Headquarters: Min...

2024-07-09 23:00 2031

Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®

* Tergase® poised to capture a fair share of the global hyaluronidase market. DAEJEON, South Korea, July 8, 2024 /PRNewswire/ -- Alteogen Inc.  (KOSDAQ:196170) announced that the Ministry of Food and Drug Safety (MFDS) of Korea approved its New Drug Application (NDA...

2024-07-08 21:00 2017

Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors

MORRISVILLE, NC., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its ...

2024-07-08 16:28 1470

Hinova Pharmaceuticals receives FDA Fast Track Designation for HP518 for Treatment of AR+ Triple-Negative Breast Cancer (TNBC)

CHENGDU, China, July 5, 2024 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (688302.SH), a leading biopharmaceutical company dedicated to developing innovative cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for HP518, an investi...

2024-07-05 21:00 4741

IASO Bio and Innovent Enhance Strategic Collaboration in Cell Therapy

SHANGHAI and NANJING, China and SAN JOSE, Calif., July 5, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innovent", H...

2024-07-05 16:30 4135

Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis

SAN FRANCISCO, July 5, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar), which is a synthetic biology-driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that ...

2024-07-05 16:07 1474

Zhejiang Doer Biologics Completes Enrollment of the Phase 1b/2a Trial Evaluating DR10624 in Obese Subjects with Modest Hypertriglyceridemia

HANGZHOU, China, July 5, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that the company has completed the enrollment in the Phase1b/2a trial ...

2024-07-05 15:56 3468

LOTTE BIOLOGICS Holds Groundbreaking for Songdo Bio Campus

* Plans to Join the Ranks of the TOP 10 Global CDMOs, Heralding a New Era in the Global CDMO Landscape SEOUL, South Korea, July 3, 2024 /PRNewswire/ -- In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEORichard W. Lee...

2024-07-04 11:17 2516

Bloomage Ranks on World Brand Lab's China 500 Most Valuable Brands List

PARSIPPANY, N.J., July 2, 2024 /PRNewswire/ -- Bloomage has once again ranked on the "China's 500 Most Valuable Brands" list by World Brand Lab, a premier global brand value evaluation agency. This milestone not only affirms the strength of Bloomage's brand but also recognizes its long-term commi...

2024-07-02 21:00 1533

PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg

* Safety Review Committee (SRC) approves single 3mg dose for the third cohort in Phase 1 trial of PMC-403 DAEJEON, South Korea, July 2, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ:208340), a clinical-stage public company developing next generation therapeutic...

2024-07-02 11:02 2153

Altos Biologics Files for Approval of Aflibercept Biosimilar

DAEJEON, South Korea, July 1, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced on July 1st that its subsidiary, Altos Biologics Inc. has submitted Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for an aflibercept bi...

2024-07-02 08:00 2793

IASO Bio Presented Clinical Data and Single-cell Analysis of Equecabtagene Autoleucel for the Treatment of Central Nervous System Autoimmunity in Oral Presentation at EAN Congress 2024

SHANGHAI, NANJING, CHINA, and SAN JOSE, Calif., July 1, 2024 /PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, presented the clinical data and single-cell an...

2024-07-01 15:43 1483

Comprehensively Covering Multiple Myeloma: IASO Bio's GPRC5D CAR-T Product RD118 Receives IND Approval from NMPA

NANJING, China, SHANGHAI and SAN JOSE, Calif., June 28, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing innovative cell therapies and antibody products, today announces thatthe investigational new d...

2024-06-28 18:59 2147

Natalia Vodianova Invests in Swiss Beauty and Longevity Brand NIANCE

ZURICH, June 27, 2024 /PRNewswire/ -- Swiss Health & bioBeauty AG, owner of the prestigious beauty and longevity brand NIANCE, announces that internationally renowned supermodel, philanthropist, and investor Natalia Vodianova has become one of the key shareholders of NIANCE. This strategic partne...

2024-06-28 11:59 1569

bioSeedin Expanded Global Licensing and Partnership Opportunities at 2024 BIO International Convention

NEWARK, Del., June 26, 2024 /PRNewswire/ -- bioSeedin, a flourishing global licensing and consulting platform, captivated attendees as an esteemed exhibitor at the BIO International Convention, the preeminent global biotech gathering. This prestigious event unfolded inSan Diego, spanning from Jun...

2024-06-26 21:00 1231

Positive Xanamem® biomarker trial published in the Journal of Alzheimer's Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau

The prospectively defined, double-blind analysis of biomarker-positive patients with mild Alzheimer's disease showed more rapid clinical progression in biomarker-positive patients, highlighting the suitability of elevated pTau for selecting patients in the on-going XanaMIA phase2b trial SYDNEY, ...

2024-06-26 20:56 2035

Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever

* Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever. * Accelerating preparations for dengue fever basket clinical trial scheduled to be conducted inBraz...

2024-06-26 09:17 1709

Porton Advanced introduces the MaxCyte ExPERT GTx Flow Electroporation instrument, continuing to provide customers with end-to-end cell and gene therapy CRO & CDMO services

SUZHOU, China, June 25, 2024 /PRNewswire/ -- Porton Advanced recently introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its cell therapy platform, marking the company as the first cell therapy CDMO in China to possess this clinical-grade flow electroporation system. T...

2024-06-25 20:00 2004
1 ... 11121314151617 ... 129